Fig. 3

IL-17A promotes the proliferation of B-ALL cells via activation of IL-17R signaling. a–d Patient B-ALL cells isolated from 4 B-ALL patients and B-ALL cell line Nalm-6 were incubated in the presence or absence of IL-17A (50 ng/ml) or IL-21 (50 ng/ml) for 7 days and then, CCK-8 assay was used to assess cell viability. Statistical data representing at least three independent experiments are presented as the viability in the presence of IL-17A or IL-21 compared with control. e Representative histograms were presented for the IL-17RA expression of patient B-ALL cells and Nalm-6 cells, determined using PE-conjugated anti-CD217 antibody (solid line) or mouse IgG1 antibody (dotted line) by flow cytometry. f Patient B-ALL cells and Nalm-6 cells were incubated with or without IL-17A (50 ng/ml) in the presence or absence of anti-IL-17R antibody (3 μg/ml) for 7 days and then, the cell viability was determined using CCK-8 assay. g, h Western blot analysis showed the phosphorylation of Akt and Stat3 were prominently increased within 2 h in Nalm-6 cells stimulated with IL-17A (50 ng/ml) or IL-21(50 ng/ml). Images representing four independent experiments were shown